Guest blogger Marcela De Vivo shares insight on some of the difficulties immigrant families face when getting help for their child with autism in this week's ASF blog post.
Researchers at University of California Irvine conducted a randomized controlled trial of sensorimotor enrichment in young boys with ASD. Behavioral and cognitive improvements in the children who received sensorimotor therapy suggest that it may be a promising treatment for ASD symptoms. The group is now conducting a larger trial that includes girls.
New findings from a small pilot study suggest cognitive enhancement therapy is a feasible and effective intervention for cognitive impairments in verbal adults with ASD. Adult participants were highly satisfied with the therapy and treatment attendance was high, indicating their willingness to participate in and commit to an intervention that they considered useful.
Early results from this pilot trial of cognitive enhancement therapy (CET) indicate that despite above-average intelligence, verbal adults with ASD can have significantly impaired neurocognition and social cognition. The authors suggest CET, which is designed to remediate both social and non-social deficits through computer-based neurocognitive training, could be useful for cognitive rehabilitation in this population.
A research team led by Gaia Novarino of the University of California, San Diego, has identified genetic mutations which cause a form of autism that could potentially be treated with dietary supplements.
This study examined school-based medication monitoring in children with ASD. Researchers found that less than half of teachers of medicated students were aware that students were taking medication and no teachers were communicating with prescribing physicians about student behavior and side effects. Since monitoring medication across settings helps physicians assess drug safety and effectiveness, the authors argue for increased communication among professionals.
Identified inactivating mutations in the gene BCKDK (Branched Chain Ketoacid Dehydrogenase Kinase) in consanguineous families with autism, epilepsy, and intellectual disability.
An estimated 32-92% of parents use complementary/alternative treatments for their children with ASD despite the lack of scientific evidence for the efficacy of these methods. In this article, researchers issue a call for a standardized way to select and evaluate treatments. Barriers to successful treatment, including high costs, limited availability, parental compliance and poor recommendations from professionals are discussed.
